公开资料显示，按2023年零售额计，颖通控股是中国（包括香港及澳门）除品牌所有者香水集团外最大 的香水集团。公品牌所有者香水集团不同，公司主要从事销售及分销从第三方品牌授权商采购的产品， 公司从中产生收入，及为该等品牌授权商进行市场部署，例如品牌管理，以及为其品牌设计及实施定制 的市场进入及扩张计划，公司并无从中产生收入。公司拥有庞大且多元化的品牌组合，不仅包括香水， 还包括彩妆、护肤品、个人护理产品、眼镜及家居香氛。公司在香水方面于中国(包括香港及澳门)取得 领先地位，乃因公司悠久的经营历史，公司在这些市场的香水行业中获得了广泛知识，并积累了相关专 业知识及丰富的资源为无数国际香水品牌进行分销及市场部署。 智通财经APP获悉，颖通控股(06883)首挂上市，公告显示，每股定价2.88港元，共发行3.334亿股股份， 每手1000股，所得款项净额约8.83亿港元。截至发稿，跌10.42%，报2.58港元，成交额1.14亿港元。 公司提供全面的销售及分销网络，涵盖中国(包括香港及澳门)大量的香水、护肤品、彩妆、个人护理产 品、眼镜及家居香氛的渠道。截至2025年3月31日，公司的产品于中国(包括香港及澳门)40 ...

智通财经6月26日电，香港恒生指数开盘跌0.53%，恒生科技指数跌0.52%，中国月子中心圣贝拉香港首 日挂牌开盘报8.45港元，招股价为6.58港元。 ...

Core Viewpoint - Zhou Shifu's stock opened over 10% higher on its first day of trading in Hong Kong, currently priced at 26.7 HKD [1] Company Overview - Zhou Shifu was founded in 2004 and is recognized as one of China's leading jewelry brands [1] - The company is primarily engaged in the research and design, production and processing, chain sales, and brand operation of jewelry [1] - Zhou Shifu offers gold jewelry products and diamond-set jewelry through both offline stores and online sales channels [1]

Core Viewpoint - The significant rise in the stock price of Guotai Junan International Holdings Limited (1788.HK) is attributed to the approval of its upgraded securities trading license, allowing it to provide virtual asset trading services, marking a new high since July 2015 [1][4]. Group 1: Company Developments - Guotai Junan International's stock price surged to HKD 3.7 per share, reflecting a 198.39% increase [1]. - The upgrade of the trading license enables clients to trade cryptocurrencies and stablecoins directly on the company's platform, enhancing its business scope [4]. - Guotai Junan International becomes the first Chinese broker in Hong Kong to offer comprehensive virtual asset trading services, including trading, advisory, and issuance of related products [4]. Group 2: Market Analysis - Analysts have positively evaluated the company's early entry into the virtual asset sector, with expectations of further upgrades among brokers with international business subsidiaries [4]. - The approval process for Guotai Junan International exceeded market expectations, indicating a proactive approach in the evolving regulatory landscape [4]. Group 3: Industry Context - Hong Kong's regulatory stance on virtual assets has shifted from cautious to open since 2022, with significant policy developments supporting the industry [5]. - The passage of the Stablecoin Bill in May 2025 reflects Hong Kong's commitment to advancing its virtual asset regulatory framework [5]. - Hong Kong is positioning itself as a global hub for virtual assets, leveraging its financial infrastructure and the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area [5].

就建议分拆而言，华夏基金(作为公募基金管理人)将设立公募基金作为封闭式公开上市基础设施证券投 资基金，并负责其日常营运。目前，预计公募基金将募集人民币13.55亿元。于建议上市时，本集团将 认购已发行基金份额总数约20%。就建议分拆而言及根据适用中国法律及法规的规定，资产支持专项计 划将由资産支持专项计划管理人设立。于建议上市完成后，公募基金将动用所得款项认购资产支持专项 计划的全部权益，其后，资産支持专项计划将动用认购款项向本集团收购项目公司的全部权益、偿还项 目公司的债务及支付公募基金及资产支持专项计划成立、交易费用。于有关收购完成后，项目公司将由 基础设施REIT持有100%权益，并将不再为公司的附属公司。于建议分拆后，基础设施REIT将不会成为 公司的附属公司，亦将不会併入公司的财务账目。 智通财经APP讯，中国海外发展(00688)发布公告，于2025年6月25日，华夏基金及中信证券向中国证监 会及深圳证券交易所提交了公募基金注册及上市的申请材料。公司已向联交所提交应用指引第15项申请 及就豁免严格遵守应用指引第15项第3(f)段有关保证配额要求的申请，且联交所已授出该豁免，并确认 公司可进行建议分 ...

Group 1: Brain-Computer Interface Standards - The National Standard for Non-Invasive Medical Devices Using Brain-Computer Interface Technology is open for public consultation, aiming to establish performance indicators and testing methods for such devices [1] - The standardization is expected to enhance international cooperation and improve regulatory efficiency, addressing the rapid development in the non-invasive neural modulation sector [1] Group 2: Pharmaceutical Industry Innovation - The head of the National Medical Products Administration emphasized the importance of supporting drug and medical device R&D innovation to strengthen China's pharmaceutical industry [2] - Key strategies include early intervention, tailored guidance for enterprises, and promoting international multi-center clinical trials to synchronize the development and approval of innovative drugs and devices [2][3] Group 3: Clinical Trials and Approvals - Shenzhou Cell announced that its product SCTB39G received approval for clinical trials in advanced solid tumors [4] - Hanyu Pharmaceutical's subsidiary received approval for the listing of the raw material drug Acetate Degarelix, which is used for treating advanced prostate cancer [6] Group 4: Market Expansion and IPOs - Kangzhe Pharmaceutical plans a secondary listing in Singapore, reflecting a trend of pharmaceutical companies expanding into Southeast Asian markets [7] - Lianya Pharmaceutical's IPO application has been accepted, focusing on complex drug formulations and high-end generic drugs [9] Group 5: Strategic Collaborations - Bayer and Tsinghua University signed a strategic cooperation agreement to enhance research in various medical fields, aiming to accelerate drug innovation [11][12] Group 6: Clinical Trial Developments - Fuhong Hanlin announced the first patient enrollment in a bridging clinical trial for its drug H, which is approved for first-line treatment of small cell lung cancer in multiple countries [13] Group 7: Corporate Leadership Changes - Fosun Pharma held a shareholder meeting to elect new board members, appointing Chen Yuqing as chairman and Liu Yi as CEO [14]

智通财经6月26日电，众安在线在港交所公告， 根据一般授权配售新H股，配售价每股18.25港元，配售 所得款项总额预计合共约39.2亿港元。 ...

公告表示，锚定"成长为国际一流的生物制药企业"的长期愿景，公司依托强大的研发平台与丰厚的创新 管线，正步入全球创新的新成长周期。创新管线的全球化布局已逐步成为公司潜在重要的增长引擎，并 展现出其核心竞争力。公司相信，本次配售事项将更好地支持公司的全球化布局，并赋予公司在管线开 发上更多支持和灵活性。这将有助于充分并加速实现公司丰厚管线的价值潜能，为公司与股东创造可持 续的长期回报。 配售股份将根据一般授权予以发行。配售股份的数目相当于本公告日期已发行股份(不包括库存股份)总 数的约3.33%；及完成配售事项后经扩大已发行股份(不包括库存股份)总数的约3.22%。假设全部配售股 份获悉数配售及认购，则配售事项所得款项总额预期约为43.098亿港元，而所得款项净额将约为42.654 亿港元。本次配售事项所得净款项将用于：(i)约90%用于推进公司丰厚的临床及临床前重点创新管线的 全球研发，以及用于公司的全球设施设备布局；及(ii)约10%将用于公司日常运营。 格隆汇6月26日丨信达生物(01801.HK)发布公告，2025年6月26日(交易时段前)，公司与联席配售代理(即 摩根士丹利及高盛)订立配售协议，据此，公 ...

Group 1: Company Overview - Cao Cao Mobility, a ride-hailing platform incubated by Geely Group, was listed on the Hong Kong Stock Exchange on June 25, becoming the largest ride-hailing platform in Hong Kong [1][2] - The company has been experiencing continuous losses for three consecutive years, with losses of approximately 2.007 billion yuan, 1.981 billion yuan, and 1.246 billion yuan from 2022 to 2024 [2] - The primary revenue source for Cao Cao Mobility is its ride-hailing services, which are expected to account for 92.6% of total revenue in 2024 [2] Group 2: Market Position and Competition - As of 2024, Cao Cao Mobility holds a market share of 5.4% in the ride-hailing sector [2] - The company is highly dependent on aggregation platforms, with orders from these platforms constituting 49.9%, 73.2%, and 85.4% of Gross Transaction Value (GTV) from 2022 to 2024 [2] - The ride-hailing industry is facing increasing competition, with leading platforms capturing significant market shares and investing heavily in operational costs and marketing subsidies [1][5] Group 3: Future Prospects and Innovations - The shared mobility sector is expected to see an increase in market share, with projections indicating that by 2030, shared mobility could account for 6.0% of the domestic transportation market [3] - Cao Cao Mobility has launched its autonomous driving platform, with plans to introduce a custom L4-level Robotaxi model by the end of 2026 [3] - Investment in autonomous driving technology is growing, as evidenced by the strategic financing of over 3 billion yuan for the Robotaxi business by Hello Chuxing, with significant backing from Ant Group and CATL [3]

Group 1: Nai Xue's Tea - Nai Xue has launched a series of light beverage and food products, enhancing its focus on the health sector [1] - The brand has undergone a visual overhaul, introducing a new logo featuring a snowflake pattern [1] - In March, Nai Xue opened over 30 "Nai Xue Green" light food stores in major cities, indicating rapid expansion [1] - In May, the average order volume per store increased by 35% year-on-year, while same-store sales grew by 28% [1] Group 2: Qunar Travel - The summer travel season is experiencing a surge, with ticket and hotel prices becoming more affordable [2] - Families and university students are the primary demographics driving travel this summer, with long-distance trips accounting for over 60% of bookings [2] - Hotel bookings for popular domestic destinations have increased by 40% year-on-year [2] - The peak travel period is expected to occur around July 5, with high demand continuing until mid-August [2] Group 3: Domestic Gold Jewelry Prices - Domestic gold jewelry prices have fallen below 1,000 yuan per gram, with major brands adjusting their prices [3] - Chow Tai Fook's gold jewelry is priced at 998 yuan per gram, down 14 yuan from the previous day [3] - The decline in prices is influenced by fluctuations in international gold prices and cautious consumer sentiment [3] Group 4: Moutai Prices - The price of Moutai has been on a downward trend, with a decrease of 85 yuan for the original box and 70 yuan for the loose bottle on June 25 [4] - Moutai's price has dropped below 2,000 yuan, 1,900 yuan, and 1,800 yuan within a month [4] - The price adjustment reflects high channel inventory and a decline in banquet consumption demand [4]